Bio-Reference Laboratories (BRLI +9.1%) pops after beating FQ1 estimates earlier. Revenue jumped 23% Y/Y on double digit sales growth as the clinical-testing company's patient count has risen and its share of complex, non-routine testing services continues to grow.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs